Cost–effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting... by Rupesh Subash, Thomas Strakosch, Michelle Zhang, Melissa Hagan, Elke Dworatzek, Agnes Kisser, Vasileios Vasilopoulos, Chloe Salter, Carissa Dickerso, Ewa Stawowczyk